Glycyrrhizin
(GL) is a well-known pharmacological inhibitor of
high mobility group box 1 (HMGB1) and is abundantly present in the
licorice root (Glycyrrhiza radix). HMGB1 protein,
a key mediator of neuroinflammation, has been implicated in several
neurological disorders, including epilepsy. Epilepsy is a devastating
neurological disorder with no effective disease-modifying treatment
strategies yet, suggesting a pressing need for exploring novel therapeutic
options. In the current investigation, using a second hit pentylenetetrazol
(PTZ) induced chronic seizure model in adult zebrafish, regulated
mRNA expression of HMGB1 was inhibited by pretreatment with GL (25,
50, and 100 mg/kg, ip). A molecular docking study suggests that GL
establishes different binding interactions with the various amino
acid chains of HMGB1 and Toll-like receptor-4 (TLR4). Our finding
suggests that GL pretreatment reduces/suppresses second hit PTZ induced
seizure, as shown by the reduction in the seizure score. GL also regulates
the second hit PTZ induced behavioral impairment and rescued second
hit PTZ related memory impairment as demonstrated by an increase in
the inflection ratio (IR) at the 3 h and 24 h T-maze trial. GL inhibited
seizure-induced neuronal activity as demonstrated by reduced C-fos
mRNA expression. GL also modulated mRNA expression of BDNF, CREB-1,
and NPY. The possible mechanism underlying the anticonvulsive effect
of GL could be attributed to its anti-inflammatory activity, as demonstrated
by the downregulated mRNA expression level of HMGB1, TLR4, NF-kB,
and TNF-α. Overall, our finding suggests that GL exerts an anticonvulsive
effect and ameliorates seizure-related memory disruption plausibly
through regulating of the HMGB1-TLR4-NF-kB axis.